Optic nerve and neuroprotection strategies

Osborne, N. N., Chidlow, G., Layton, C. J., Wood, J. P. M., Casson, R. J. and Melena, J. (2004) Optic nerve and neuroprotection strategies. Eye, 18 11: 1075-1084. doi:10.1038/sj.eye.6701588


Author Osborne, N. N.
Chidlow, G.
Layton, C. J.
Wood, J. P. M.
Casson, R. J.
Melena, J.
Title Optic nerve and neuroprotection strategies
Journal name Eye   Check publisher's open access policy
ISSN 0950-222X
1476-5454
Publication date 2004
Sub-type Critical review of research, literature review, critical commentary
DOI 10.1038/sj.eye.6701588
Open Access Status
Volume 18
Issue 11
Start page 1075
End page 1084
Total pages 10
Place of publication London, United Kingdom
Publisher Nature Publishing
Language eng
Formatted abstract
Background: Experimental studies have yielded a wealth of information related to the mechanism of ganglion cell death following injury either to the mylinated ganglion cell axon or to the ganglion cell body. However, no suitable animal models exist where injury can be directed to the optic nerve head region, particularly the unmylinated ganglion cell axons. The process of relating the data from the various animal models to many different types of optic neuropathies in man must, therefore, be cautious.

Results: Extensive studies on the isolated optic nerve have yielded valuable information on the way white matter is affected by ischaemia and how certain types of compounds can attenuate the process. Moreover, there are now persuasive data on how ganglion cell survival is affected when the ocular blood flow is reduced in various animal models. As a consequence, the molecular mechanisms involved in ganglion cell death are fairly well understood and various pharmacological agents have been shown to blunt the process when delivered before or shortly after the insult.

Conclusions: A battery of agents now exist that can blunt animal ganglion cell death irrespective of whether the insult was to the ganglion cell body or the mylinated axon. Whether this information can be applied for use in patients remains a matter of debate, and major obstacles need to be overcome before the laboratory studies may be applied clinically. These include the delivery of the pharmacological agents to the site of ganglion cell injury and side effects to the patients. Moreover, it is necessary to establish whether effective neuroprotection is only possible when the drug is administered at a defined time after injury to the ganglion cells. This information is essential in order to pursue the idea that a neuroprotective strategy can be applied to a disease like glaucoma, where ganglion cell death appears to occur at different times during the lifetime of the patient.
Keyword Ophthalmology
Neuroprotection
Glaucoma
Ischaemia
Optic nerve
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status Non-UQ
Additional Notes Copyright is owned by the journal publisher

Document type: Journal Article
Sub-type: Critical review of research, literature review, critical commentary
Collection: School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 59 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 62 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Sat, 12 Jul 2014, 15:55:17 EST by Christopher James Layton on behalf of Surgery - Greenslopes Private Hospital